Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

526
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
526
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

589
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
589
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

587
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
587
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

470
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
470
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

619
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
619
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

365
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
365

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

OBESITY AND THYROID FUNCTION IN OBESE WOMEN: A PILOT STUDY.

Georgian medical news·2025
Same author

Focus on malignant ventricular premature contractions.

Annales de cardiologie et d'angeiologie·2023
Same author

Investigation of structural, optical and electrical conductivity of a new organic inorganic bromide: [C<sub>12</sub>H<sub>17</sub>N<sub>2</sub>]<sub>2</sub>ZnBr<sub>4</sub>.

RSC advances·2023
Same author

Biological activities and wound healing potential of a water-soluble polysaccharide isolated from Glycyrrhiza glabra in Wistar rat.

Brazilian journal of biology = Revista brasleira de biologia·2022
Same author

First homozygous large deletion in EDARADD gene associated with a severe form of anhidrotic ectodermal dysplasia.

Journal of the European Academy of Dermatology and Venereology : JEADV·2018
Same author

[Correlations between insulin sensitivity with anthropometric and metabolic parameters in type 2 diabetics].

Annales de cardiologie et d'angeiologie·2018
Same journal

[Heart and climate].

Herz·2026
Same journal

Multidimensional psychosocial screening in routine cardiac care: preliminary findings from a cross-sectional survey.

Herz·2026
Same journal

[Noise and the heart].

Herz·2026
Same journal

[The cardiovascular exposome: areas of action for prevention and practical cardiology].

Herz·2026
Same journal

Relationship between HAVOC score and new-onset atrial fibrillation in patients with ST elevation myocardial infarction.

Herz·2026
Same journal

Interventional treatment of atrioventricular valves.

Herz·2026
See all related articles

Related Experiment Video

Updated: Feb 11, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

Risk stratification in hypertrophic cardiomyopathy.

S Marrakchi1,2, I Kammoun3,4, E Bennour3,4

  • 1Department of Cardiology, Abderrahmane Mami Hospital, Ariana, Tunisia. marrakchi.sonia@yahoo.fr.

Herz
|April 27, 2018
PubMed
Summary
This summary is machine-generated.

Sudden cardiac death (SCD) risk in hypertrophic cardiomyopathy (HCM) is challenging. The HCM Risk-SCD model aids in identifying high-risk patients for implantable cardioverter-defibrillator (ICD) therapy, improving decision-making for primary prevention.

Keywords:
HypertrophyImplantable cardioverter-defibrillatorMyocardiumRisk assessmentSudden cardiac death

More Related Videos

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.2K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

Related Experiment Videos

Last Updated: Feb 11, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K
A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.2K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

Area of Science:

  • Cardiology
  • Genetics
  • Preventive Medicine

Background:

  • Sudden cardiac death (SCD) is a severe complication of hypertrophic cardiomyopathy (HCM).
  • Accurate risk stratification is crucial for timely intervention with implantable cardioverter-defibrillators (ICDs).
  • Current risk stratification data for HCM patients can be conflicting.

Purpose of the Study:

  • To review existing data on SCD in HCM.
  • To offer a clinical perspective on risk stratification challenges and decision-making for ICD implantation.
  • To assess the implementation of global HCM expert guidelines.

Main Methods:

  • Systematic review of available data on SCD in HCM.
  • Analysis of clinical perspectives on risk stratification models.
  • Evaluation of current guideline implementation.

Main Results:

  • The HCM Risk-SCD model provides an individualized risk estimate for SCD.
  • This model assists clinicians in decision-making for primary SCD prevention.
  • Risk stratification remains a key factor before considering ICD implantation.

Conclusions:

  • Improved risk stratification is essential for managing HCM patients at risk of SCD.
  • The HCM Risk-SCD model offers a valuable tool for clinical decision-making.
  • Consistent application of guidelines is vital for optimal patient care.